Clinical trials: Irinotecan
Colorectal Cancer, Colorectal Carcinoma
A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
This study will assess the safety of RAD001 when given together with cetuximab and irinotecan
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
- Trial name
- NCT00478634
- Testing
- RAD001, Cetuximab, Irinotecan
- Where
- 16 sites in United States
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Gastroesophageal Cancer
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma.
- Trial name
- TroFuse-015 (NCT06356311)
- Testing
- Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan
- Where
- 168 sites in United States, Belgium and 22 more
- Volunteers
- 473 people
- Sponsor
- Merck Sharp & Dohme LLC
Ewing's Sarcoma
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
A two-part trial in patients with metastic Ewing's sarcoma. Participants in Part 1 will be randomized to receive either Vigil immunotherapy or gemcitabine and docetaxel with the objective of comparing the overall survival between…
- Trial name
- NCT02511132
- Testing
- Vigil, Temozolomide, Irinotecan
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Gradalis, Inc.
Metastatic Pancreatic Cancer
A Multi-center, Single-arm, Prospective Non-interventional Study to Investigate the Safety Profiles and Effectiveness of Liposomal Irinotecan (ONIVYDE®) in Combination with 5-fluorouracil (5-FU) and Leucovorin (LV) in Chinese Patients with Metastatic Pancreatic Cancer As Approval Condition (SEOPAC)
The aim of this phase 4 study is to evaluate the safety profile of ONIVYDE in China mainland. Primary objective To characterize the safety of ONIVYDE when used under standard clinical practice in China mainland on the following…
- Trial name
- SEOPAC (NCT06688240)
- Volunteers
- 120 people
- Sponsor
- Servier (Tianjin) Pharmaceutical Co. LTD.
Esophageal Carcinoma
Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer
In this study, participants with advanced or metastatic squamous cell carcinoma of the esophagus that has progressed after first-line standard therapy will be randomized to receive either single agent SHR-1210 or the…
- Trial name
- NCT03099382
- Testing
- camrelizumab, Docetaxel, Irinotecan
- Where
- 2 sites in China
- Volunteers
- 457 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Colorectal Cancer
A Study in Second Line Metastatic Colorectal Cancer
The purpose of this study is to compare overall survival in participants with metastatic colorectal cancer treated with either ramucirumab and FOLFIRI or placebo and FOLFIRI.
- Trial name
- NCT01183780
- Testing
- Ramucirumab, Irinotecan, Folinic Acid
- Where
- 213 sites in United States, Argentina and 24 more
- Volunteers
- 1,072 people
- Sponsor
- Eli Lilly and Company
Advanced Cancer, Metastatic Cancer
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART0380 that can be given safely to participants…
- Conditions
- Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04657068
- Testing
- ART0380, Gemcitabine, Irinotecan
- Where
- 88 sites in United States, France and 2 more
- Volunteers
- 542 people
- Sponsor
- Artios Pharma Ltd
Metastatic Colorectal Cancer, Colon Cancer
Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer
The goal of this clinical study is to determine the dosing and safety of labetuzumab govitecan (formerly known as IMMU-130; hMN-14-SN38, antibody-drug conjugate) in participants with colorectal cancer.
- Conditions
- Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
- Trial name
- NCT01605318
- Testing
- Labetuzumab Govitecan (LG)
- Where
- 7 sites in United States
- Volunteers
- 92 people
- Sponsor
- Gilead Sciences
Colorectal Cancer, Diarrhea
Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
RATIONALE: Octreotide may be effective in preventing diarrhea that is caused by treatment with irinotecan. PURPOSE: Randomized phase III trial to study the effectiveness of octreotide in preventing diarrhea in patients who are…
- Trial name
- NCT00006269
- Testing
- irinotecan hydrochloride, octreotide acetate
- Where
- 2 sites in United States
- Volunteers
- 89 people
- Sponsor
- Novartis
Solid Tumors
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
This is a three arm study to determine the maximum tolerated dose (MTD) of ABT-263 when administered in combination with erlotinib (Arm A), to determine the maximum tolerated dose (MTD) of ABT-263 when administered in combination…
- Trial name
- NCT01009073
- Testing
- ABT-263, erlotinib, irinotecan (3-week schedule)
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Neoplasms, Solid Tumors
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
This is a Phase 1/1B, non-randomized, open-label, dose-escalation study of robatumumab (SCH 717454, MK-7454) administered in combination with chemotherapy in pediatric participants with solid tumors, to be conducted in…
- Conditions
- Neoplasms, Solid Tumors, Bone Cancer, Kidney Tumor
- Trial name
- NCT00960063
- Testing
- Temozolomide, Vincristine, Ifosfamide
- Volunteers
- 4 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, Colorectal Cancer
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or…
- Conditions
- Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer
- Trial name
- NCT03872947
- Testing
- TRK-950, Irinotecan, Leucovorin
- Where
- 14 sites in United States, France
- Volunteers
- 138 people
- Sponsor
- Toray Industries, Inc
HER2 IHC3+ Advanced Colorectal Cancer
A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
This is a Phase III, randomized, open-label, active-controlled, multicenter study designed to evaluate the efficacy and safety of Injection TQB2102 compared with investigator's choice of treatment in subjects with Human Epidermal…
- Trial name
- NCT07483684
- Testing
- TQB2102 Injection, Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets
- Where
- 48 sites in China
- Volunteers
- 142 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Metastatic Colorectal Cancer
Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
The purpose of this study is to determine whether SCT200 is safe and tolerant in the treatment of metastatic colorectal cancer
- Trial name
- NCT02211443
- Testing
- Recombinant full human Anti-EGFR Monoclonal Antibody
- Volunteers
- 21 people
- Sponsor
- Sinocelltech Ltd.
Colorectal Cancer
A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)
This is a Phase Ib, open-label, multicenter, dose-escalation study designed to assess if PRO95780 in combination with two different irinotecan-containing regimens is safe and tolerable in patients with metastatic colorectal…
- Trial name
- NCT00497497
- Testing
- bevacizumab, cetuximab, FOLFIRI regimen
- Volunteers
- 20 people
- Sponsor
- Genentech, Inc.
Advanced Malignant Tumors
A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) and AK117#AntiCD47 Antibody# combined with or without chemotherapy in advanced malignant tumors
- Trial name
- NCT05235542
- Testing
- AK104, AK117, Capecitabine tablets
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Akeso
Colorectal Cancer
Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill more tumor cells.
- Trial name
- NCT00026273
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- 15 sites in Austria, Belgium and 8 more
- Sponsor
- Pfizer
Cervical Cancer
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
This trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cervical cancer that has spread to other parts of the body (metastatic) or has come…
- Trial name
- innovaTV 301 (NCT04697628)
- Testing
- tisotumab vedotin, topotecan, vinorelbine
- Where
- 211 sites in United States, Argentina and 23 more
- Volunteers
- 502 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Advanced or Metastatic Colorectal Cancer
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to assess the recommended phase 2 combination dose (RP2CD) of amivantamab when added to SoC chemotherapy (Ph1b…
- Trial name
- OrigAMI-1 (NCT05379595)
- Testing
- Amivantamab IV, Fluorouracil, Leucovorin
- Where
- 53 sites in United States, Belgium and 9 more
- Volunteers
- 225 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Colorectal Cancer
Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer
The primary purpose of this study is to evaluate the clinical response and safety of CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type…
- Trial name
- CRC009 (NCT01550055)
- Testing
- CMAB009 plus Irinotecan, Irinotecan-only and sequential-CMAB009
- Volunteers
- 512 people
- Sponsor
- Shanghai Zhangjiang Biotechnology Limited Company